Prenatal neurogenesis induction therapy normalizes brain structure and function in Down syndrome mice.

Area of Science:

• Neuroscience
• Genetics
• Developmental Biology

Background:

• Down syndrome (DS), caused by trisomy 21, is the leading genetic cause of intellectual disability.
• Current treatments for DS do not address neurocognitive impairment, highlighting a critical unmet medical need.
• Prenatal diagnosis of DS is possible, but therapeutic interventions are lacking.

Purpose of the Study:

• To identify and evaluate a novel therapeutic agent for mitigating neurocognitive deficits in Down syndrome.
• To investigate the potential of a DYRK1A inhibitor for rescuing neurodevelopmental abnormalities in DS models.

Main Methods:

• Screening of neural stem cells (NSCs) to identify a growth inducer with DYRK1A inhibitory activity.
• Testing the compound ALGERNON in Ts65Dn-derived neurospheres and human DS-derived NSCs.
• Administering ALGERNON orally to pregnant dams and DS mouse models to assess effects on neurogenesis and cortical development.
• Evaluating behavioral outcomes in DS offspring following prenatal ALGERNON exposure.

Main Results:

• The identified compound, ALGERNON, potently inhibits DYRK1A and rescues proliferative deficits in DS-derived neural stem cells.
• Oral administration of ALGERNON restored NSC proliferation and increased neurogenesis in murine models of DS.
• Prenatal ALGERNON therapy prevented aberrant cortical formation in DS mouse embryos.
• ALGERNON administration prevented the development of abnormal behaviors in DS offspring.

Conclusions:

• ALGERNON demonstrates significant potential as a prenatal therapy to prevent the neurogenic phenotype associated with Down syndrome.
• Targeting DYRK1A with ALGERNON offers a promising strategy for rescuing neurocognitive impairment in DS.
• These findings suggest a novel therapeutic approach to mitigate the lifelong effects of Down syndrome.